CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Sage Therapeutics, Inc. - SAGE CFD

43.44
0.02%
0.25
Low: 42.37
High: 43.65
Market Trading Hours* (UTC) Opens on Tuesday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.25
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0308%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0137%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

SAGE Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 43.43
Open* 42.81
1-Year Change* 15.64%
Day's Range* 42.37 - 42.37
52 wk Range 27.36-45.74
Average Volume (10 days) 0.56204
Average Volume (3 months) 9.58049
Market Cap 2211.38
P/E Ratio N/A
Shares Outstanding 59493700
Revenue 6.464
EPS -8.6262
Dividend (Yield %) N/A
Beta 1.16283
Next Earnings Date Feb 22, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 2, 2022 43.43 3.33 8.30% 40.10 43.59 40.10
Dec 1, 2022 40.89 0.65 1.62% 40.24 41.25 39.50
Nov 30, 2022 40.93 2.68 7.01% 38.25 41.09 38.24
Nov 29, 2022 38.42 1.21 3.25% 37.21 38.66 37.20
Nov 28, 2022 37.87 0.67 1.80% 37.20 38.69 37.19
Nov 25, 2022 37.71 0.57 1.53% 37.14 37.84 36.53
Nov 23, 2022 37.36 0.54 1.47% 36.82 37.61 36.60
Nov 22, 2022 37.08 2.14 6.12% 34.94 37.17 34.55
Nov 21, 2022 34.95 -0.66 -1.85% 35.61 35.68 34.59
Nov 18, 2022 35.90 0.68 1.93% 35.22 36.59 35.22
Nov 17, 2022 35.01 0.57 1.66% 34.44 35.59 33.41
Nov 16, 2022 35.01 -1.93 -5.22% 36.94 36.94 34.95
Nov 15, 2022 35.21 -1.46 -3.98% 36.67 36.78 34.95
Nov 14, 2022 35.91 0.68 1.93% 35.23 36.78 34.79
Nov 11, 2022 35.52 0.99 2.87% 34.53 35.72 34.46
Nov 10, 2022 34.96 1.49 4.45% 33.47 35.18 33.07
Nov 9, 2022 32.13 -1.50 -4.46% 33.63 33.63 32.04
Nov 8, 2022 33.84 -0.80 -2.31% 34.64 35.80 33.82
Nov 7, 2022 33.81 -0.85 -2.45% 34.66 34.88 33.66
Nov 4, 2022 34.73 -1.75 -4.80% 36.48 36.53 33.93

Sage Therapeutics, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 0 0 90.273 6.868 1114.2 6.308
Total Operating Expense 160.163 273.155 483.511 714.992 517.974 467.217
Selling/General/Admin. Expenses, Total 39.407 62.878 201.404 345.777 196.952 183.498
Research & Development 120.756 210.277 282.107 368.815 292.714 283.166
Operating Income -160.163 -273.155 -393.238 -708.124 596.226 -460.909
Interest Income (Expense), Net Non-Operating 1.211 3.099 20.334 27.804 9.597 2.883
Other, Net -0.035 -0.064 0.022 0.082 0.25 0.134
Net Income Before Taxes -158.987 -270.12 -372.882 -680.238 606.073 -457.892
Net Income After Taxes -158.987 -270.12 -372.882 -680.238 606.073 -457.892
Net Income Before Extra. Items -158.987 -270.12 -372.882 -680.238 606.073 -457.892
Net Income -158.987 -270.12 -372.882 -680.238 606.073 -457.892
Income Available to Common Excl. Extra. Items -158.987 -270.12 -372.882 -680.238 606.073 -457.892
Income Available to Common Incl. Extra. Items -158.987 -270.12 -372.882 -680.238 606.073 -457.892
Diluted Net Income -158.987 -270.12 -372.882 -680.238 606.073 -457.892
Diluted Weighted Average Shares 33.4928 38.1137 46.1212 50.8338 53.0031 58.6702
Diluted EPS Excluding Extraordinary Items -4.7469 -7.08722 -8.08483 -13.3816 11.4347 -7.8045
Diluted Normalized EPS -4.7469 -7.08722 -8.08483 -13.3816 11.9581 -7.8045
Total Extraordinary Items 0
Revenue 90.273 6.868 1114.2 6.308
Cost of Revenue, Total 0.4 0.565 0.553
Gross Profit 6.468 1113.64 5.755
Unusual Expense (Income) 27.743 0
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 1.583 1.643 1.44 1.642 1.582
Revenue 1.583 1.643 1.44 1.642 1.582
Cost of Revenue, Total 0.187 0.148 0.131 0.087 0.286
Gross Profit 1.396 1.495 1.309 1.555 1.296
Total Operating Expense 98.09 109.664 132.334 127.129 124.781
Selling/General/Admin. Expenses, Total 39.847 43.346 48.706 51.599 46.477
Research & Development 58.056 66.17 83.497 75.443 78.018
Operating Income -96.507 -108.021 -130.894 -125.487 -123.199
Interest Income (Expense), Net Non-Operating 0.708 0.732 0.692 0.751 1.168
Other, Net 0.035 0.044 0.031 0.024 -0.024
Net Income Before Taxes -95.764 -107.245 -130.171 -124.712 -122.055
Net Income After Taxes -95.764 -107.245 -130.171 -124.712 -122.055
Net Income Before Extra. Items -95.764 -107.245 -130.171 -124.712 -122.055
Net Income -95.764 -107.245 -130.171 -124.712 -122.055
Income Available to Common Excl. Extra. Items -95.764 -107.245 -130.171 -124.712 -122.055
Income Available to Common Incl. Extra. Items -95.764 -107.245 -130.171 -124.712 -122.055
Diluted Net Income -95.764 -107.245 -130.171 -124.712 -122.055
Diluted Weighted Average Shares 58.3742 58.5826 58.8195 58.8997 59.0289
Diluted EPS Excluding Extraordinary Items -1.64052 -1.83066 -2.21306 -2.11736 -2.06772
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -1.64052 -1.83066 -2.21306 -2.11736 -2.06772
Unusual Expense (Income) 0 0 0
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 402.579 525.075 944.695 1035.09 2122.37 1800.64
Cash and Short Term Investments 397.479 518.848 922.776 1008.39 2099.55 1742.3
Cash & Equivalents 168.517 306.235 190.943 126.705 1661.08 294.233
Short Term Investments 228.962 212.613 731.833 881.688 438.467 1448.06
Prepaid Expenses 5.1 6.227 21.919 26.7 22.821 39.841
Total Assets 404.531 529.937 952.705 1084.15 2159.25 1825.29
Property/Plant/Equipment, Total - Net 1.388 4.013 5.643 42.897 31.819 19.125
Property/Plant/Equipment, Total - Gross 1.93 5.086 7.859 47.396 38.907 24.098
Accumulated Depreciation, Total -0.542 -1.073 -2.216 -4.499 -7.088 -4.973
Other Long Term Assets, Total 0.564 0.849 2.367 6.16 5.057 5.52
Total Current Liabilities 35.169 51.951 86.03 112.128 67.204 85.193
Accounts Payable 12.817 9.35 34.036 15.266 3.691 10.45
Accrued Expenses 6.06 15.962 19.875 33.202 23.931 26.703
Notes Payable/Short Term Debt 0 0 0 0 0 0
Other Current Liabilities, Total 16.292 26.639 32.119 63.66 39.582 48.04
Total Liabilities 36.014 54.462 89.734 139.495 86.912 96.257
Total Long Term Debt 0 0 0 0 0 0
Other Liabilities, Total 0.845 2.511 3.704 27.367 19.708 11.064
Total Equity 368.517 475.475 862.971 944.655 2072.33 1729.03
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.004 0.005 0.005 0.005 0.006 0.006
Additional Paid-In Capital 688.959 1066.06 1827.02 2587.32 3109.81 3227.47
Retained Earnings (Accumulated Deficit) -320.327 -590.447 -963.329 -1643.57 -1037.49 -1495.39
Treasury Stock - Common -0.017 -0.113 -0.211 -0.4 -0.4 -0.4
Other Equity, Total -0.102 -0.029 -0.515 1.295 0.415 -2.66
Total Liabilities & Shareholders’ Equity 404.531 529.937 952.705 1084.15 2159.25 1825.29
Total Common Shares Outstanding 37.2222 42.0029 46.8883 51.8772 58.3084 58.937
Total Receivables, Net 18.506
Accounts Receivable - Trade, Net 18.506
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 2051.87 1988.6 1901.7 1800.64 1682.24
Cash and Short Term Investments 2004.02 1911.31 1843.17 1742.3 1625.24
Cash & Equivalents 899.25 514.158 422.165 294.233 178.674
Short Term Investments 1104.77 1397.16 1421 1448.06 1446.57
Total Receivables, Net 24.766 48.438 24.185 18.506 19.797
Accounts Receivable - Trade, Net 24.766 48.438 24.185 18.506 19.797
Prepaid Expenses 23.083 28.846 34.343 39.841 37.206
Total Assets 2080.7 2015.47 1927.18 1825.29 1705.7
Property/Plant/Equipment, Total - Net 24.171 22.008 20.339 19.125 17.599
Property/Plant/Equipment, Total - Gross 28.823 26.683 25.388 24.098 22.847
Accumulated Depreciation, Total -4.652 -4.675 -5.049 -4.973 -5.248
Other Long Term Assets, Total 4.661 4.868 5.144 5.52 5.86
Total Current Liabilities 62.011 71.898 78.942 85.193 77.703
Accounts Payable 3.285 2.917 4.733 10.45 7.129
Accrued Expenses 11.633 16.374 19.468 26.703 15.434
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 47.093 52.607 54.741 48.04 55.14
Total Liabilities 77.422 85.963 91.526 96.257 87.201
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 15.411 14.065 12.584 11.064 9.498
Total Equity 2003.28 1929.51 1835.65 1729.03 1618.5
Redeemable Preferred Stock 0 0 0
Common Stock 0.006 0.006 0.006 0.006 0.006
Additional Paid-In Capital 3137.16 3170.69 3207.03 3227.47 3247.54
Retained Earnings (Accumulated Deficit) -1133.26 -1240.5 -1370.67 -1495.39 -1617.44
Treasury Stock - Common -0.4 -0.4 -0.4 -0.4 -0.4
Other Equity, Total -0.236 -0.285 -0.306 -2.66 -11.201
Total Liabilities & Shareholders’ Equity 2080.7 2015.47 1927.18 1825.29 1705.7
Total Common Shares Outstanding 58.4068 58.7704 58.8324 58.937 59.0662
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -158.987 -270.12 -372.882 -680.238 606.073 -457.892
Cash From Operating Activities -118.678 -219.277 -260.671 -528.706 664.28 -378.182
Cash From Operating Activities 0.281 0.531 1.143 2.283 2.63 4.182
Non-Cash Items 22.55 35.136 91.856 142.591 95.306 94.034
Changes in Working Capital 17.478 15.176 19.212 6.658 -39.729 -18.506
Cash From Investing Activities -230.015 15.462 -512.461 -143.156 442.684 -1002.45
Capital Expenditures -1.421 -1.36 -2.86 -5.751 -0.345 -0.372
Other Investing Cash Flow Items, Total -228.594 16.822 -509.601 -137.405 443.029 -1002.08
Cash From Financing Activities 330.982 341.818 659.358 607.624 426.762 13.334
Financing Cash Flow Items -0.599 -0.179 -1.244 -2.503 -1.385
Issuance (Retirement) of Stock, Net 331.581 341.997 660.602 610.127 426.762 14.719
Net Change in Cash -17.711 138.003 -113.774 -64.238 1533.73 -1367.3
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -95.764 -203.009 -333.18 -457.892 -122.055
Cash From Operating Activities -109.086 -211.855 -280.681 -378.182 -107.8
Cash From Operating Activities 2.582 3.475 3.849 4.182 0.275
Non-Cash Items 13.842 37.454 72.911 94.034 20.897
Changes in Working Capital -29.746 -49.775 -24.261 -18.506 -6.917
Cash From Investing Activities -658.816 -947.204 -972.187 -1002.45 -9.558
Other Investing Cash Flow Items, Total -658.816 -947.204 -972.187 -1002.08 -9.389
Cash From Financing Activities 5.623 11.688 13.504 13.334 1.799
Issuance (Retirement) of Stock, Net 5.623 12.484 14.3 14.719 1.799
Net Change in Cash -762.279 -1147.37 -1239.36 -1367.3 -115.559
Capital Expenditures 0 0 -0.372 -0.169
Financing Cash Flow Items -0.796 -0.796 -1.385
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Fidelity Management & Research Company LLC Investment Advisor 10.6188 6317534 340441 2022-09-30 LOW
Biogen Inc Corporation 10.491 6241473 0 2022-03-31 LOW
Wellington Management Company, LLP Investment Advisor/Hedge Fund 8.2908 4932518 182895 2022-09-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 8.0305 4777657 45026 2022-09-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 5.8503 3480534 -40731 2022-09-30 LOW
Bellevue Asset Management AG Investment Advisor 4.9933 2970678 -2500 2022-09-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.9664 2954683 20619 2022-09-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 3.5514 2112860 35326 2022-09-30 LOW
Boxer Capital, L.L.C. Hedge Fund 1.8389 1094000 0 2022-09-30 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 1.8082 1075765 422868 2022-09-30 LOW
Marshall Wace LLP Investment Advisor/Hedge Fund 1.6853 1002660 -612646 2022-09-30 HIGH
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.6203 963954 9581 2022-09-30 LOW
Columbia Threadneedle Investments (US) Investment Advisor/Hedge Fund 1.4915 887353 465920 2022-09-30 LOW
Palo Alto Investors LP Hedge Fund 1.4311 851409 0 2022-09-30 LOW
JP Morgan Asset Management Investment Advisor 1.4288 850019 -52711 2022-09-30 LOW
BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 1.3972 831236 590352 2022-09-30 LOW
Goldman Sachs Asset Management, L.P. Investment Advisor 1.3729 816796 145243 2022-09-30 LOW
Point72 Asset Management, L.P. Hedge Fund 1.3474 801600 -457700 2022-09-30 HIGH
Invus Public Equities Advisors, LLC Investment Advisor 1.2606 750000 300000 2022-09-30 LOW
Janus Henderson Investors Investment Advisor/Hedge Fund 1.2294 731423 -35626 2022-09-30 LOW

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
475000+

Traders

71000+

Active clients monthly

$51000000+

Monthly investing volume

$30000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Sage Therapeutic Company profile

About SAGE Therapeutics Inc

SAGE Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing medicines with debilitating disorders of the brain. The Company's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD), in adults. The Company's products also include ZULRESSO (Brexanolone) CIV Injection, Zuranolone (SAGE-217), SAGE-324 and SAGE-718. Its next advanced product candidate is SAGE-217, is an oral compound that is in Phase III clinical development in PPD and depressive disorder (MDD). Zuranolone is a neuroactive steroid that, like brexanolone, is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. SAGE-324 is a GABAA receptor positive allosteric modulator intended for chronic oral dosing and conducting a placebo-controlled Phase II clinical trial evaluating the safety and efficacy of SAGE-324 in the treatment of essential tremor.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, SAGE Therapeutics Inc revenues decreased 99% to $6.3M. Net loss totaled $457.9M vs. income of $606.1M. Revenues reflect Collaboration revenue decrease from $1.11B to $0K, Product decrease of 6% to $6.3M. Net loss reflects Stock-based Compensation in R&D increase of 17% to $49.7M (expense), Stock-based Compensation in SGA increase of 6% to $54.9M (expense), Other income (expense).

Equity composition

Common Stock, $0.0001 Par, 07/14, auth. 120M shares,. 24,961,926 issd,. Insiders owns approx. 20.03%.

Industry: Bio Therapeutic Drugs

215 1st St
CAMBRIDGE
MASSACHUSETTS 02142
US

Income Statement

People also watch

US100

11,792.40 Price
-1.540% 1D Chg, %
Long position overnight fee -0.0168%
Short position overnight fee 0.0061%
Overnight fee time 22:00 (UTC)
Spread 1.8

Oil - Crude

77.46 Price
-3.610% 1D Chg, %
Long position overnight fee -0.0091%
Short position overnight fee -0.0054%
Overnight fee time 22:00 (UTC)
Spread 0.03

Natural Gas

5.60 Price
-9.920% 1D Chg, %
Long position overnight fee 0.0392%
Short position overnight fee -0.0631%
Overnight fee time 22:00 (UTC)
Spread 0.005

BTC/USD

16,973.40 Price
-0.970% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 60.00

Still looking for a broker you can trust?

Join the 475.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading